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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a major but neglected public
health problem. Currently 1.4% of the England population has a clinical diagnosis of COPD, but the
true burden of the disease has not been known with certainty, as many cases remain undiagnosed.
Methods: A mathematical model based on cross sectional data from a representative sample of
the population in England (the Heath Survey for England 2001, n = 10,750) was developed allowing
estimates on the prevalence of COPD (defined based on the presence of airflow obstruction) to
be obtained. Logistic regression analysis was used to investigate and choose risk factors for
inclusion in the model and to derive the prevalence estimates based on the strength of association
between selected risk factors and the outcome COPD. The model allows the prevalence to be
estimated in populations at national level and also at regional and large local areas, based on their
compositions according to age, sex, smoking and ethnicity, and on area degrees of urbanisation and
deprivation. We applied the model to measure the prevalence of COPD in England and in some
sub-groups of the population within the country.
Results: The prevalence of COPD in England is estimated as 3.1% (3.9% in men and 2.4% in
women) in the population over 15 years of age, and 5.3% (6.8% in men and 3.9% in women) in 45
year-olds and over. There was a 7-fold variation in the prevalence across subgroups of the
population, with lowest values in Asian women from wealthy rural areas (1.7%), and highest in black
men from deprived urban areas (12.5%).
Conclusion: The model can be used to estimate population prevalence of COPD from large
general practices to national level, and as a tool to identify areas of high levels of unmet needs for
COPD priority health actions. The results from the model highlight the importance of including
variables other than age, sex and smoking, i.e. levels of deprivation, urbanisation and ethnicity, when
estimating population prevalence of COPD. The model should be validated at local level and
incorporated into case-finding strategies.
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Background
Chronic obstructive pulmonary disease (COPD) is a
chronic condition characterised by progressive airflow
obstruction, which is not completely reversible. COPD
accounts for nearly 30,000 deaths each year in the United
Kingdom (UK), corresponding to 5.7 percent of adult
male and 4 percent of adult female deaths, including a sig-
nificant number of premature deaths. In addition, 1.4%
of the population consult their general practitioners (GPs)
for COPD each year. It accounts for 2% of hospital admis-
sion spells and over 3 percent of bed-days in adults [1],
costing the NHS £800 million, and leading to 24 million
working days lost each year [2].
As expected, the prevalence of COPD is higher in smokers
and in men, and it increases with age. Other risk factors of
public health importance include air pollution [3], socio-
economic deprivation [3], occupational exposures [3,4]
and possibly ethnicity [5-7]. There is considerable varia-
tion in the reported prevalence of COPD.
Models using smoking rates to estimate COPD prevalence
have been previously proposed [8-10], but none has direct
relevance to the UK. We therefore developed a model
(Model-HSE) to estimate the prevalence of COPD based
on existing data from the Health Survey for England
(HSE) 2001 [11], which has nevertheless not been used
for this purpose before. It uses the main risk factors for
COPD reported in the literature, particularly those that
are easily measured and for which information is readily
available. This report explains how the model was devel-
oped, and uses the population of England to illustrate its
application.
Methods
Data sources
The distribution of COPD in the population of England
was based on the HSE 2001 findings for lung function
parameters and their association with relevant risk factors.
The methods used in the HSE 2001 are described in detail
elsewhere [11]. In brief, the survey included a representa-
tive sample of the population who had their lung function
evaluated using a portable spirometer with a calibration
device (Vitalograph 'Escort Spirometer'). Comprehensive
data on risk factors were also collected as part of the sur-
vey. The data refer to 5,269 men and 6,133 women over
15 years old with valid lung function measures. This cor-
responds to 98% of men and 95% of women visited by a
research nurse as part of the survey. For 99.3% of these,
data were available for all of age-group, smoking status,
ethnicity and degree of urbanisation. Data were available
for deprivation score and all of the above risk factors in
94.3% of the final sample, which was used for the multi-
variate analysis. This included 4,970 men and 5779
women.
COPD was defined according to British Thoracic Society
(BTS) criteria [12], based on the values of forced expira-
tory volume in 1 second (FEV1) and the forced vital capac-
ity (FVC) i.e. FEV1/FVC < 0.70 and FEV1<80% predicted
using British reference values derived from the HSE [13].
Model construction
The choice of variables for inclusion in the model was
based on logistic regression analysis that examined pre-
dictors of COPD using the HSE 2001 dataset. Explanatory
variables obtained from the HSE dataset and included in
the final model were (categories of each variable shown in
brackets): gender, age group (15–34 year olds, 10 year age
groups from 35 up to 74 years of age and 75 year olds and
over), smoking status (smoker, former smoker, never
smoker), ethnicity (White, Black or Black British, and
Asian or Asian British), area of residence (rural, urban and
suburban) and area based index of deprivation (quintile
of deprivation score based on Index of Multiple Depriva-
tion[14]).
The  baseline odds of COPD (in non-smokers under 35
years old) were obtained directly from the data. Separate
baseline odds were estimated for each gender, and also
according to ethnicity, area of residence and area-based
deprivation score.
The logistic model was used to derive the odds ratios and
prevalence ratios for COPD for subjects with various com-
binations of risk factors in relation to baseline. The preva-
lence in each age group, gender, ethnic group, area of
residence and level of deprivation, and smoking status
category were derived from the odds, using the formula:
Prevalence = odds/(1 + odds).
Model application
The input variables, which could be defined by the relevant
user, e.g. at Primary Care Trust, include age-group, gender,
smoking prevalence by gender and age, area of residence,
area based deprivation score and ethnic distribution of
the population.
Model outputs
The main model outputs are the prevalence of COPD by
gender for the relevant geographic area, at national,
regional or local level, as defined by the user. To illustrate
the use of the model, we have used here population inputs
for England, based on the mid-2005 estimated popula-
tion distribution [15] and the national smoking preva-
lence by age-group and gender for 2004–2005 [16].
Model assumptions
The model assumptions include: i) The real prevalence of
COPD in non-smokers under 35 years of age (baseline
prevalence) is the same as the prevalence in non-smokersPopulation Health Metrics 2007, 5:8 http://www.pophealthmetrics.com/content/5/1/8
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of the same age group and gender in the 2001 HSE popu-
lation; ii) The ratio of odds and prevalence of COPD in
the various age groups compared to the baseline group is
the same as in the HSE for each gender, smoking status
and other risk factors in the model; iii) the risks in those
falling within each of the risk categories are uniform.
We also obtained the prevalence of COPD considering
alternative scenarios, which assume that: a) the preva-
lence of COPD in under 35s or under 40s is uniform
across smoking status in each gender, and is equal to the
average baseline prevalence found at the HSE (therefore it
does not consider any increase in risk due to smoking in
this age group); or b) the prevalence of COPD is zero in
under 35s or in under 40s; or c) ethnicity does not have an
effect on the risk of COPD, and the risks in white popula-
tions apply to all ethnic groups.
Results
Risk factors for COPD and selection of variables for 
Model-HSE
Table 1 shows the results of the univariate and final regres-
sion logistic models assessing risk factors for COPD. Risk
of COPD is significantly lower in women than in men
(odds ratio (OR) = 0.64; 95% CI = 0.54 – 0.76; p < 0.001).
As gender was shown to modify the effect of other varia-
bles on the outcome, the analyses were carried out sepa-
rately for men and women. No other significant
interactions were found in the data, including between
age-group and smoking status.
The final model shows age group and smoking history are
the strongest predictors of COPD in both genders. Resi-
dence in urban areas and possibly black ethnicity are also
associated with increased risk, particularly in women. Liv-
ing in more deprived areas is associated with increased
risk in men, but not in women. Being Asian appears to be
protective in women, although this association did not
reach statistical significance.
Application of HSE-model to England population
Table 2 and Figure 1 show the prevalence of COPD by age
and gender in England. The overall prevalence in the pop-
ulation over 15 years of age was 3.1% (3.9% in men and
2.4% in women). For those over 45 years old, the esti-
mated prevalence was 5.3% (6.8% and 3.9% in men and
women respectively). This corresponds to over 1.3 million
people in England with COPD, of whom nearly 800 thou-
sand or 60% are men.
The assumption that ethnicity is not associated with being
a case of COPD, i.e. that all population has the same risk
of whites, did not change the total national prevalence
estimates considerably (1,297 thousand in 15 year-olds
and over and 1,065 thousand over 45s under this assump-
tion). When we considered the risk of COPD in under 35s
as equal to the average baseline risk in this age group (in
non-smokers), the total number of cases estimated was
reduced by 60,800, resulting in an overall prevalence of
1.25 million or 3% (3.8% in men and 2.3% in women).
Considering the risk in all over 40s as equal to the average
baseline risk, the total number of cases is reduced further
to 1,.223,200 (3.0% overall prevalence; 3.7% in men and
2.3% in women). If we consider the risk in under 35s as
inexistent, the total number of estimated cases decreases
to 1,185,700 (2.9% overall prevalence; 3.4% in men and
2.2% in women). Assuming the more extreme situation of
zero risk in all under 40s, the prevalence comes down to
1,128,550 (2.7% overall; or 3.4% in men and 2.11% in
women), representing a decrease of 174,500 compared to
the original estimates The latter estimates assume that all
cases of airflow obstruction in the younger age groups are
due to other diagnoses than COPD, such as asthma.
Table 3 shows the estimated prevalences of COPD in
urban, suburban and rural England, based on the national
population distribution and smoking prevalence. The val-
ues in brackets show the estimated average prevalence for
areas in the lower and highest quintiles of deprivation.
The average prevalence in over 45s varies 4-fold, with the
highest values in men in deprived urban areas, and the
lowest in women in wealthy rural areas. When the effect
of ethnicity is also considered, the variation in prevalence
reaches 7-fold, from 1.7% in Asian women from rural
areas in the lower quintile of deprivation to 12.5% in
black men from urban areas in the upper quintile of dep-
rivation.
Discussion
We developed a mathematical model that enables the
prevalence of COPD to be estimated based on informa-
tion that is easily available to Primary Care Trusts and
many individual general practices. The model takes into
account the increasing prevalence of COPD with age and
smoking, and the modifying effect of gender. It also con-
siders a higher risk of COPD among those living in urban
environments and in areas of higher deprivation, and in
black ethnicities.
As expected, the risk associated with smoking and former-
smoking is higher in men compared to women. This may
be related to their longer history and intensity of smoking,
as compared to women. The effects of ethnicity and area
of residence are more evident in women, among whom
deprivation score is not apparently relevant, after other
variables are considered. Urban environment increases
the risk of COPD, possibly through higher air pollution
levels. Social deprivation may increase the risk of COPD
through complex mechanisms in addition to the higher
prevalence of smoking. This may include different smok-Population Health Metrics 2007, 5:8 http://www.pophealthmetrics.com/content/5/1/8
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Table 1: Risk factors for COPD included in the final prevalence model
Variable Odds Ratio (95% CI) (univariate model) Odds Ratio (95% CI) (final logistic model)
MEN (n = 4970)
Smoking Status (P < 0.001) (P < 0.001)
- Never smoker 1 1
- Former smoker 3.63 (2.54 – 5.21) 2.18 (1.48 – 3.23)
- Current Smoker 3.81 (2.64 – 5.52) 4.50 (3.01 – 6.74)
Age-group (in years of age) (P < 0.001) (P < 0.001)
- <35 1 1
- 35–44 1.65 (0.86 – 3.17) 1.94 (0.99 – 3.78)
- 45–54 2.45 (1.33 – 4.50) 2.66 (1.41 – 4.99)
- 55–64 6.91 (4.02 – 11.89) 7.92 (4.46 – 14.07)
- 65–74 10.40 (6.08 – 17.80) 12.69 (7.12 – 22.60)
- 75+ 12.15 (6.78 – 21.76) 16.02 (8.57 – 29.94)
Area of residence (P = 0.02) (P = 0.25)
- Urban 1 1
- Suburban 0.70 (0.50 – 0.97) 0.74 (0.51 – 1.06)
- Rural 0.58 (0.39 – 0.86) 0.72 (0.46 – 1.15)
Ethnicity (P = 0.64) (P = 0.95)
- White 1 1
- Black/Black British 1.20 (0.48 – 2.99) 1.17 (0.44 – 3.10)
- Asian/Asian British 0.69 (0.28 – 1.70) 0.97 (0.37 – 2.51)
Quintile of Multiple Deprivation Score 1.22 (1.11 – 1.34) (P < 0.001) 1.17 (1.05 – 1.31) (P = 0.005)
WOMEN (n = 5779)
Smoking Status (P < 0.001) (P < 0.001)
- Never smoker 1 1
- Former smoker 1.70 (1.07 – 2.64) 1.26 (0.79 – 2.01)
- Current Smoker 3.53 (2.43 – 5.14) 4.11 (2.74 – 6.15)
Age-group (in years of age) (P < 0.001) (P < 0.001)
- <35 1 1
- 35–44 1.08 (0.53 – 2.19) 1.35 (0.65 – 2.79)
- 45–54 2.34 (1.28 – 4.30) 2.69 (1.42 – 5.09)
- 55–64 4.18 (2.34 – 7.47) 6.03 (3.26 – 11.15)
- 65–74 5.36 (2.99 – 9.61) 8.04 (4.33 – 14.91)
- 75+ 5.34 (2.79 – 10.22) 10.40 (5.18 – 20.87)
Area of residence (P = 0.01) (P = 0.04)
- Urban 1 1
- Suburban 0.62 (0.42 – 0.92) 0.59 (0.39 – 0.90)
- Rural 0.47 (0.29 – 0.77) 0.55 (0.32 – 0.96)
Ethnicity (P = 0.19) (P = 0.50)
- White 1 1
- Black/Black British 1.14 (0.42 – 3.12) 1.81 (0.64 – 5.14)
- Asian/Asian British 0.24 (0.03 – 1.76) 0.60 (0.08 – 4.47)
Quintile of Multiple Deprivation Score 1.18 (1.05 – 1.34) (P = 0.005) 1.11 (0.98 – 1.27) (P = 0.11)Population Health Metrics 2007, 5:8 http://www.pophealthmetrics.com/content/5/1/8
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ing habits (the model does not take into account duration
and intensity of smoking as such information is not read-
ily available), and a higher likelihood of exposure to other
risk factors, which are not easily measured, such as passive
exposure to tobacco smoking, history of respiratory infec-
tions, and less access to health services and information.
Ethnic differences in susceptibility are less clear and less
well understood, but might involve a combination of
behavioural, environmental and possibly genetic factors.
We estimated the overall prevalence of COPD in England
as 3.1% in people over 15 years old and 5.3% in those
over 45 years old. The model illustrates the huge inequal-
ities in the prevalence of COPD across England, with
extreme risks in black men in urban deprived areas in one
end of the risk spectrum, and Asian women in the lowest
deprived rural areas, in the opposite end, between whom
the risk of COPD varies 7-fold on average. Thus simpler
models that do not take into account such variations in
prevalence across population groups, or the extrapolation
of national COPD prevalence figures for smaller areas,
would be inappropriate for local use.
A systematic review of good quality COPD prevalence
studies yielded estimates for England of between 4% and
10% [17]. The Health Needs Assessment report suggests a
prevalence of 5% for men and 3% for women of middle
age and upwards [18]. Our results are similar to the latter,
but not as high as suggested by some of the studies used
for the former review. The decreasing trend in smoking
prevalence in England is likely to lead to slow reductions
in the real prevalence of COPD. However, major causes of
variations in estimates include differences in the popula-
tions and in the diagnostic criteria used [19]. This is illus-
trated by the finding of a prevalence of 13.3% in over 35s
in the HSE survey, when a different definition of COPD
was used [20]. That study also calculated the prevalence
directly from the survey data, differently from our study,
where estimates were extrapolated for the population of
England.
The figures estimated by the Model-HSE for England are
in general slightly lower than, but comparable with other
studies on COPD using the same BTS definition, i.e. 4.5%
in Norway [21], 6.8% in the US [22] and 6.8% in white
males 40–60 years old in Spain [23]. They are also similar
to the overall prevalence of 6.1% found in the
NICECOPD study for Belfast white population aged 40 to
69 years [24]. The slightly lower estimated prevalence in
our study may be largely explained by the lower smoking
prevalence in England, but also by differences in the study
populations, and the larger study size of the Health Survey
for England.
Comparisons of our results with studies that used other
definitions of COPD are difficult to interpret. Estimates
based on self-reported symptoms tend to overestimate the
prevalence. This is because diagnostic specificity is
reduced as other respiratory diseases may be misdiag-
nosed as COPD, although asymptomatic cases of airflow
obstruction will be missed. On the other hand, medically
Estimated real prevalence of COPD in England population of  median deprivation score by age-group and gender Figure 1
Estimated real prevalence of COPD in England population of 
median deprivation score by age-group and gender.
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Table 2: Number and proportion of people estimated to have COPD by age group and gender in England (estimates for 2005)
Age-group (Years) Men Number (%)* Women Number (%) Both sexes Number (%)
15–44 137,530 (1.30) 93,450 (0.89) 230,980 (1.10)
45–54 75,720 (2.38) 64,840 (2.00) 140,560(2.19)
55–64 198,400(6.90) 122,440 (4.11) 320,840 (5.48)
65–74 199,840(10.03) 105,740 (4.81) 305,580 (7.29)
75+ 172,700(11.65) 132,400 (5.55) 305,100 (7.89)
Total 15+ 784,190 (3.89) 518,870 (2.41) 1,303,060(3.15)
Total 45+ 646,660 (6.76) 425,420 (3.92) 1,072,080(5.27)
* Values in brackets indicate age-gender specific prevalence rates (%) of COPDPopulation Health Metrics 2007, 5:8 http://www.pophealthmetrics.com/content/5/1/8
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diagnosed COPD tends to under-estimate the true preva-
lence of the disease, as diagnostic sensitivity is reduced.
Compared to other commonly used COPD spirometric-
based case definitions, the BTS is based on quite conserv-
ative cut-off points, yielding relatively low estimate values
[10,17].
A main advantage of the Model-HSE is that it is based on
high quality data from a large representative sample of the
population, and uses standard and specific diagnostic cri-
teria for COPD, which is based on lung function rather
than symptoms. Response rates were high in the survey
with the achieved samples matching the target popula-
tions closely [25]. Prevalence estimates are based on the
strength of association between key risk factors for COPD,
including the effects of ethnicity, area of residence and
deprivation, which were shown to be independent risk
factors for COPD in the HSE survey. This represents a sig-
nificant advantage in relation to previous COPD preva-
lence models [8,9], which were based only on smoking
status, age and gender (also used in the Model-HSE) of
mostly white populations outside the United Kingdom.
The input data are usually readily available at local level.
The model uses current smoking status (never, former,
current) as surrogates for total exposure to cigarette
smoke, and is therefore not ideal to predict short term
effects of changes in smoking prevalence (e.g. following
intervention), due to long latent periods, large time lag
between intervention and effects, and irreversibility of dis-
ease. However, the model is not static and will be updated
over time, as parameters' values change, e.g. smoking
prevalence (in England there are regular estimates of
smoking prevalence at sub-regional level). Noteworthy,
since intensity and duration of smoking (and thus smok-
ing associated risk of COPD) tend to be lower in younger
populations [25], the model may slightly overestimate the
prevalence in young people. Another reason for preva-
lence overestimation in young ages is a possible misclassi-
fication of cases of asthma into COPD (note reversibility
test was not used in the HSE). We dealt with these by pro-
viding alternative estimates for the prevalence of COPD,
applying baseline or nil prevalence rates in all those under
35 and under 40 years old. These brought the overall prev-
alence estimates down by 0.1% to 0.4%. The model also
relies on the quality of smoking and other data, and does
not take into account competing causes of morbidity and
mortality in the population, e.g. cardiovascular disease
and lung cancer, which may affect prevalence of COPD.
Moreover, it still needs correction for populations with
significant occupational exposures. There is some degree
of imprecision in the estimates, which are larger when the
rates are estimated for smaller populations or sub-groups,
such as ethnic minorities and specific age-groups. There-
fore we recommend that it is used primarily to derive
overall population prevalence estimates, rather than esti-
mates within population sub-groups. Further validation
with a representative sample of the UK population includ-
ing large proportions of people from ethnic minorities is
still needed, before it may be reliably used in small popu-
lation groups, such as GP practices and in ethnic minori-
ties. We are currently planning to validate the model at
practice level in North West London and investigating the
feasibility of two COPD case-finding strategies.
Respiratory function indices have been shown to be pre-
dictive of mortality from respiratory disease, cardiovascu-
lar disease and all cause mortality [26,27]. Airflow
limitation may precede the development of significant
symptoms of COPD by many years and its progression is
directly linked to the continuing exposure to risk factors,
particularly tobacco smoking. As COPD is difficult to
diagnose clinically (without spirometry) in its milder
forms, it is often diagnosed late – the average age at diag-
nosis of COPD in the UK is 67 years [28].
Widespread use of spirometry allowing early detection of
airflow obstruction has been increasingly advocated as it
enables early management of COPD [29]. Stopping smok-
ing prevents the development of COPD, or slows its
progress and reduces the risk of hospital admissions [30].
Smoking cessation programmes are highly cost-effective,
and crucially, have been specifically shown to be cost-
effective when directed to individuals with asymptomatic
airway obstruction [31]. This is because smokers may be
motivated to attempt to quit when given a diagnosis of
airflow limitation [32]. The incremental cost effectiveness
ratio (ICER) of opportunistic COPD case-finding for this
Table 3: Estimated prevalence P (percent) of COPD in England and according to area of residence
Area P men age 15+ P men age 45+ P women 15+ P women 45+
Urban 4.86 (3.65–6.47) 8.41 (6.35–11.12) 3.68 (2.91–4.39) 5.95 (4.71–7.05)
Suburban 3.74 (2.75–4.94) 6.50 (4.79–8.55) 2.23 (1.79–2.69) 3.62 (2.91–4.36)
Rural 3.65 (2.75–4.85) 6.35 (4.80–8.40) 2.05 (1.67–2.53) 3.33 (2.72–4.10)
England 3.89 (2.89–5.16) 6.76 (5.04–8.92) 2.41 (1.94–2.92) 3.92 (3.15–4.72)
* Values in brackets correspond to mean values in extreme quintiles of deprivation score, or approximately the 10th and 90th percentiles of the 
prevalence distribution.Population Health Metrics 2007, 5:8 http://www.pophealthmetrics.com/content/5/1/8
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purpose is a cost per life year gained of £713.16 and a cost
per QALY of £814.56 4 [1].
The magnitude of undiagnosed cases can be ascertained
by comparing the model estimates with the recorded prev-
alence of COPD, to indicate the extent of unmet needs in
COPD. In the UK this is facilitated by GP performance
payments for COPD management through the Quality
and Outcomes Framework (QOF) of the GP Contract
based on an electronic register of all patients with diag-
nosed COPD. If this is linked to case finding and interven-
tion, there is a potential for reducing the population
burden and progression of the disease.
The average QOF-diagnosed prevalence of COPD in Eng-
land reported in 2004–5 through the Quality and Out-
comes Framework of the GP Contract was only1.4% [33].
This indicates that around 600,000 or nearly half of the
1.3 million COPD cases remain undiagnosed. A relatively
large number of these individuals live in London or North
of England (data not shown). Many of such cases will con-
tinue their risk behaviours and eventually present to the
health services at later stages as more severe cases, possibly
through emergency hospital admissions. Many of them
will become high intensity users of health services, with
considerable costs to individuals, the NHS and society. An
audit of 80,000 COPD admissions showed that 70% of
them are of patients not previously admitted with the con-
dition (Bird M, personal communication).
The Model-HSE may be freely obtained directly from the
authors and is publicly available on the Eastern Region
Health Observatory website [34]. It may be used, with the
qualifications stated above, by general practices and pri-
mary care trusts (PCTs), in England, and indeed in other
user defined populations in the country and probably in
other countries of the UK i.e. Wales, Scotland and North-
ern Ireland. General practices can use their own data on
the population distribution by age-group and gender,
smoking prevalence, ethnicity, degree of urbanisation and
deprivation score for the area where the practice is located,
to obtain indicative figures on the prevalence of COPD in
their population. Data from the Primary Care Trust where
the practice is located may be used as a proxy (with any
relevant adjustments) in cases where practice specific data
are not available. In addition it may be valid in Western
populations that are not too dissimilar from England.
Conclusion
We believe that compared to previous models and preva-
lence estimates, the HSE-Model offers the most reliable
estimates for England and the United Kingdom. It recog-
nises deprivation, urban living and ethnicity as independ-
ent risk factors for COPD, which are taken into account in
the estimates derived, in addition to smoking, age and
gender. The model gives prevalence estimates for areas of
varying sizes, including large populations at local level,
however, the precision of the estimates will be higher for
larger areas.
The overall prevalence of COPD in England is estimated
as 1.3 million, of whom as many as 600,000 people may
be unaware of their diagnosis, therefore missing the
opportunity of benefiting from early interventions. This
emphasises the importance of active case finding and the
model can be used to identify areas with a high level of
unmet needs, i.e. with a high proportion of undiagnosed
disease, where the benefits of case finding would be opti-
mised. This strategy may also have an impact on reducing
health inequalities, due to the socio-economic class gradi-
ent in COPD prevalence. The model should be validated,
and case-finding strategies using the model should be
evaluated for their cost-effectiveness.
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